Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CMPS Stock Summary
Top 10 Correlated ETFs
CMPS
In the News

COMPASS Pathways earns repeat ‘Buy' rating and US$60 price target on adjusted trial design for COMP360
Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their ‘Buy' rating and US$60 price target for COMPASS Pathways after the mental health care company adjusted the trial design for its COMP360 phase 3 program investigating psilocybin for treatment-resistant depression (TRD). “We are not making any major changes to our model post-4Q22 results,” the analysts wrote in a note to clients.

2 Growth Stocks With Incredible Potential in the Next 5 Years
Biotech stocks are risky, but high-potential plays can pay off big. Compass Pathways is making progress towards commercializing its first therapy.

COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor Conference
LONDON, March 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three upcoming events as follows:

COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023
Conference call to be held at 8:00am ET (1:00pm UK) Conference call to be held at 8:00am ET (1:00pm UK)

3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street
These stocks are risky. But they just might deliver huge gains if analysts are right.

7 Tempting Sin Stocks to Buy for Promising Profits
Following a rough year, investors seeking positive returns might want to consider going a bit controversial with sin stocks. Understandably, with the political winds turning progressive, people nowadays turn a stink eye toward cynicism.

The 7 Most Promising Psychedelic Stocks to Buy in February
Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.

Psychedelic Sunday: Competitive Strategies
Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?

All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong Buy
COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?
Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and Geron (GERN) have performed compared to their sector so far this year.
CMPS Financial details
CMPS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.77 | -1.14 | -3.55 | -1.79 | -2.16 | |
Operating cash flow per share | -0.57 | -1.03 | -2.44 | -1.69 | -2.48 | |
Free cash flow per share | -0.58 | -1.04 | -2.44 | -1.7 | -2.5 | |
Cash per share | 1.33 | 1.45 | 11.2 | 6.83 | 3.37 | |
Book value per share | -0.83 | -1.76 | 11.57 | 7.11 | 4.27 | |
Tangible book value per share | -0.83 | -1.76 | 11.57 | 7.11 | 4.27 | |
Share holders equity per share | -0.83 | -1.76 | 11.57 | 7.11 | 4.27 | |
Interest debt per share | 0 | 1.22 | 0 | 0.09 | 0.05 | |
Market cap | 500.51M | 500.51M | 809.48M | 883.95M | 340.76M | |
Enterprise value | 477.6M | 496.63M | 619.16M | 614.32M | 199.49M | |
P/E ratio | -37.86 | -25.52 | -13.42 | -12.32 | -3.72 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -51.07 | -28.1 | -19.56 | -13.05 | -3.23 | |
PFCF ratio | -50.4 | -27.84 | -19.5 | -12.98 | -3.21 | |
P/B Ratio | -34.83 | -16.47 | 4.12 | 3.11 | 1.88 | |
PTB ratio | -34.83 | -16.47 | 4.12 | 3.11 | 1.88 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -36.19 | -25.42 | -10.29 | -8.61 | -2.2 | |
EV to operating cash flow | -48.73 | -27.88 | -14.96 | -9.07 | -1.89 | |
EV to free cash flow | -48.09 | -27.62 | -14.92 | -9.02 | -1.88 | |
Earnings yield | -0.03 | -0.04 | -0.07 | -0.08 | -0.27 | |
Free cash flow yield | -0.02 | -0.04 | -0.05 | -0.08 | -0.31 | |
Debt to equity | -2.84 | -2.07 | 0.04 | 0.06 | 0.09 | |
Debt to assets | 1.54 | 1.94 | 0.03 | 0.05 | 0.08 | |
Net debt to EBITDA | 1.74 | 0.2 | 3.16 | 3.78 | 1.56 | |
Current ratio | 14.24 | 1.35 | 29.36 | 19.55 | 12.29 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0.74 | 0.91 | 0.69 | 0.94 | 1.15 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.01 | 0 | 0 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -5.91 | -2.62 | -1.17 | -1.91 | -1.81 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 3.79 | 6.71 | 30.4 | 16.94 | 14.4 | |
ROIC | 0.62 | 1.12 | 0.29 | 0.34 | 1.18 | |
Return on tangible assets | -0.5 | -0.61 | -0.3 | -0.24 | -0.46 | |
Graham Net | -0.94 | -1.96 | 11.05 | 6.63 | 3.27 | |
Working capital | 24.43M | 8.3M | 195.51M | 280.19M | 176.06M | |
Tangible asset value | -14.37M | -30.39M | 196.56M | 284.41M | 181.28M | |
Net current asset value | -14.48M | -30.61M | 195.51M | 278.81M | 175.64M | |
Invested capital | 0 | -0.69 | 0 | 0.01 | 0.01 | |
Average receivables | 0 | 3.68M | 5.5M | 8.5M | 13.42M | |
Average payables | 0 | 1.01M | 2.04M | 2.66M | 3.66M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.92 | 0.65 | -0.31 | -0.25 | -0.5 | |
Capex per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.61 | -0.5 | -0.5 | -0.43 | -0.73 | |
Operating cash flow per share | -0.53 | -0.55 | -0.42 | -0.45 | -1.07 | |
Free cash flow per share | -0.54 | -0.55 | -0.43 | -0.45 | -1.07 | |
Cash per share | 6.53 | 5.8 | 4.88 | 4.07 | 3.37 | |
Book value per share | 6.8 | 6.17 | 5.29 | 4.58 | 4.27 | |
Tangible book value per share | 6.8 | 6.17 | 5.29 | 4.58 | 4.27 | |
Share holders equity per share | 6.8 | 6.17 | 5.29 | 4.58 | 4.27 | |
Interest debt per share | 0.09 | 0.07 | 0.07 | 0.05 | 0.05 | |
Market cap | 924.52M | 541.85M | 459.58M | 456.3M | 340.76M | |
Enterprise value | 654.9M | 301.16M | 255.39M | 285.48M | 199.49M | |
P/E ratio | -9.01 | -6.4 | -5.46 | -6.21 | -2.75 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -41.33 | -23.43 | -25.53 | -23.99 | -7.52 | |
PFCF ratio | -41.16 | -23.35 | -24.95 | -24 | -7.5 | |
P/B Ratio | 3.25 | 2.09 | 2.05 | 2.35 | 1.88 | |
PTB ratio | 3.25 | 2.09 | 2.05 | 2.35 | 1.88 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -25.68 | -14.36 | -12.23 | -15.72 | -6.49 | |
EV to operating cash flow | -29.28 | -13.02 | -14.18 | -15.01 | -4.4 | |
EV to free cash flow | -29.16 | -12.98 | -13.87 | -15.01 | -4.39 | |
Earnings yield | -0.03 | -0.04 | -0.05 | -0.04 | -0.09 | |
Free cash flow yield | -0.02 | -0.04 | -0.04 | -0.04 | -0.13 | |
Debt to equity | 0.06 | 0.05 | 0.06 | 0.15 | 0.09 | |
Debt to assets | 0.05 | 0.05 | 0.06 | 0.13 | 0.08 | |
Net debt to EBITDA | 10.57 | 11.47 | 9.78 | 9.4 | 4.6 | |
Current ratio | 19.55 | 22.82 | 17.53 | 7.4 | 12.29 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0.87 | 1.09 | 0.86 | 1.04 | 1.46 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.02 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1.79 | -1.52 | -4.43 | 0 | -1.11 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 9.68 | 8.36 | 7.68 | 6.67 | 8.37 | |
ROIC | 0.11 | 0.12 | 0.15 | 0.18 | 0.34 | |
Return on tangible assets | -0.09 | -0.08 | -0.09 | -0.08 | -0.16 | |
Graham Net | 6.34 | 5.74 | 4.85 | 3.69 | 3.27 | |
Working capital | 280.19M | 254.87M | 218.76M | 188.92M | 176.06M | |
Tangible asset value | 284.41M | 259.57M | 224.59M | 194.56M | 181.28M | |
Net current asset value | 278.81M | 254.03M | 217.94M | 188.49M | 175.64M | |
Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Average receivables | 9.64M | 12.41M | 15.28M | 17.54M | 16.87M | |
Average payables | 2.65M | 2.31M | 2.7M | 11.62M | 12.32M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.09 | -0.08 | -0.09 | -0.09 | -0.17 | |
Capex per share | 0 | 0 | -0.01 | 0 | 0 |
CMPS Frequently Asked Questions
What is COMPASS Pathways plc stock symbol ?
COMPASS Pathways plc is a GB stock and trading under the symbol CMPS
What is COMPASS Pathways plc stock quote today ?
COMPASS Pathways plc stock price is $9.33 today.
Is COMPASS Pathways plc stock public?
Yes, COMPASS Pathways plc is a publicly traded company.